Selected outcome
Before Apr 1, 2027
Before Apr 1, 2027
Stored quote · checking the venue
- Scheduled end
- Mar 31, 2027 ET
- Resolution source
- Food and Drug Administration (opens in a new tab)
Price
Loading price history.
Markets
- Before Oct 1, 2027
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?
68%
Open · ~$51 24h · ~$602 vol
Bid 64¢ · Ask 71¢
- Before Apr 1, 2027
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Apr 1, 2027?
No quote
Open · ~$0 24h · ~$0 vol
Ask 8¢
- Before Jul 1, 2027
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027?
14%
Open · ~$0 24h · ~$3 vol
Bid 9¢ · Ask 18¢
- Before Jan 1, 2028
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?
88%
Open · ~$0 24h · ~$867 vol
Bid 83¢ · Ask 92¢
- Before Jul 1, 2028
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?
95%
Open · ~$0 24h · ~$0 vol
Bid 91¢ · Ask 99¢
Event statistics
How this resolves
- Scheduled end
- Mar 31, 2027 ET
- Resolution source
- Trading
- Closed
- In review
- Resolved
Rules text
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Apr 1, 2027, then the market resolves to Yes.